A Rice University professor has developed a new early warning system and planning tool for the city of Houston. Photo courtesy of Kinder Institute

It's no secret: certain areas around Houston are at a high risk of flooding. And risks associated with such natural disasters become even more substantial in the middle of a pandemic.

"What if first responders have to go to a shelter, a nursing home, or another facility where there's COVID, right in the middle of a flood," Phil Bedient, director of Rice University's Severe Storm Prediction, Education and Evacuation from Disasters (SSPEED) Center, asks in a statement.

His solution? To develop a new early warning system and planning tool for the city of Houston to help hospitals and other critical facilities on the watersheds of Brays, Sims, Hunting and White Oak bayous respond.

"The idea is to provide a tool that can help emergency managers better deal with situations with multiple risks," he says.

Dubbed the Flood Information and Response System (FIRST), the tool is a radar-based flood assessment, mapping, and early-warning system based on more than 350 maps that simulate different combinations of rainfall over various areas of the watershed. The maps are compared to a weather radar and stream gauges on the bayous to alert users of likely scenarios during a weather event.

FIRST was derived from the Rice/Texas Medical Center Flood Alert System (FAS), which Bedient created 20 years ago. The latest iteration, FAS5, debuted in 2020. Since the product's creation it has accurately alerted users in more that 60 storms and has warned hospital officials in the TMC of the threat of rising water in the area more than two hours before it would eventually occur, according to a statement.

FIRST was funded by federal CARES Act dollars and commissioned by the Houston Health Department, following concerns that overflows at wastewater treatment plants could potentially expose communities to the COVID-19, Loren Hopkins, chief environmental science officer for the Houston Health Department and professor in the practice of statistics at Rice, says in a statement.

"The FIRST model assessed what areas and facilities are at highest risk of overflows that could spread SARS-CoV-2 and other pathogens during flooding and similar events," Hopkins added. "During a flood, the information gained through this system will inform the public health response to control the spread of pathogens that could make people sick."

CARES funds for FIRST's development were approved in the fall and Rice University undergraduates jumped at the opportunity to build out the product by the December 31 deadline, using hydrologic software and maps they had created with training from Bedient about a year prior.

"They performed herculean tasks," Bedient says. "Our deadline was hard and fast, and they helped us deliver the operational project and report on time."

FIRST was reported to have worked well during May's deluge, and will continue to be refined as more data, storms, and floodwaters arise. A demo is available to test online.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”